Scoop.it

3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca | The Motley Fool

Rob LW - 0
They could add up to make Moderna a much bigger winner for investors than either of the two big pharma stocks.
Read more

VIROLOGYCONSULT.COM

Virology, antivirals and vaccines

Who are we?

63,083,565
Confirmed cases
Updated on 30th November 2020 7:18 am
1,465,309
Total deaths
Updated on 30th November 2020 7:18 am
43,065,975
Total recovered
Updated on 30th November 2020 7:18 am
18,552,281
Total active cases
Updated on 30th November 2020 7:18 am
Scoop.it

3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca | The Motley Fool

Rob LW - 0
They could add up to make Moderna a much bigger winner for investors than either of the two...
Read more
Scoop.it

Coronavirus vaccine results drive hope for economic recovery | Business | The Guardian

Rob LW - 0
Guardian analysis shows retail sales booming and financial markets picking up around world...
Read more
Scoop.it

Will everyone in the world have access to a Covid vaccine? – video explainer | Society | The Guardian

Rob LW - 0
The Guardian's international correspondent, Michael Safi, explains why 'vaccine nationalisation' could scupper global efforts to kill the virus and examines what is being done to...
Read more
Scoop.it

COVID-19: Two million more Moderna jabs secured as PM appoints new vaccine minister | UK News

Rob LW - 0
Doses of the jab 95%-effective jab could begin in the Spring, but it has yet to be approved by the UK regulator.
Read more
Scoop.it

How Iceland hammered COVID with science

Rob LW - 0
The tiny island nation brought huge scientific heft to its attempts to contain and study the coronavirus. Here’s what it learnt.
Read more
Scoop.it

3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca | The Motley Fool

Rob LW - 0
They could add up to make Moderna a much bigger winner for investors than either of the two big pharma stocks.
View Post
Scoop.it

3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca | The Motley Fool

Rob LW - 0
They could add up to make Moderna a much bigger winner for investors than either of the two big pharma stocks.
View Post
Scoop.it

Coronavirus vaccine results drive hope for economic recovery | Business | The Guardian

Rob LW - 0
Guardian analysis shows retail sales booming and financial markets picking up around world...
View Post
Scoop.it

Will everyone in the world have access to a Covid vaccine? – video explainer | Society | The Guardian

Rob LW - 0
The Guardian's international correspondent, Michael Safi, explains why 'vaccine nationalisation' could scupper global efforts to kill the virus and examines what is being done to...
View Post
Scoop.it

COVID-19: Two million more Moderna jabs secured as PM appoints new vaccine minister | UK News

Rob LW - 0
Doses of the jab 95%-effective jab could begin in the Spring, but it has yet to be approved by the UK regulator.
View Post

Quick Read

Scoop.it

3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca | The Motley Fool

Rob LW - 0
They could add up to make Moderna a much bigger winner for investors than either of the two big pharma stocks.
Scoop.it

3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca | The Motley Fool

Rob LW - 0
They could add up to make Moderna a much bigger winner for investors than either of the two big pharma stocks.
Scoop.it

Coronavirus vaccine results drive hope for economic recovery | Business | The Guardian

Rob LW - 0
Guardian analysis shows retail sales booming and financial markets picking up around world...
Scoop.it

Will everyone in the world have access to a Covid vaccine? – video explainer | Society | The Guardian

Rob LW - 0
The Guardian's international correspondent, Michael Safi, explains why 'vaccine nationalisation' could scupper global efforts to kill the virus and examines what is being done to...
Scoop.it

COVID-19: Two million more Moderna jabs secured as PM appoints new vaccine minister | UK News

Rob LW - 0
Doses of the jab 95%-effective jab could begin in the Spring, but it has yet to be approved by the UK regulator.
Scoop.it

How Iceland hammered COVID with science

Rob LW - 0
The tiny island nation brought huge scientific heft to its attempts to contain and study the coronavirus. Here’s what it learnt.

Prevention Strategy

Scoop.it

3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca | The Motley Fool

Rob LW - 0
They could add up to make Moderna a much bigger winner for investors than either of the two big pharma stocks.
Scoop.it

3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca | The Motley Fool

Rob LW - 0
They could add up to make Moderna a much bigger winner for investors than either of the two big pharma stocks.
Read more
Scoop.it

Will everyone in the world have access to a Covid vaccine? – video explainer | Society | The Guardian

Rob LW - 0
The Guardian's international correspondent, Michael Safi, explains why 'vaccine nationalisation' could scupper global efforts to kill the virus and examines what is being done to...
Read more
Scoop.it

COVID-19: Two million more Moderna jabs secured as PM appoints new vaccine minister | UK News

Rob LW - 0
Doses of the jab 95%-effective jab could begin in the Spring, but it has yet to be approved by the UK regulator.

Global Impact

Scoop.it

3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca | The Motley Fool

Rob LW - 0
They could add up to make Moderna a much bigger winner for investors than either of the two big pharma stocks.
Read more
Scoop.it

Coronavirus vaccine results drive hope for economic recovery | Business | The Guardian

Rob LW - 0
Guardian analysis shows retail sales booming and financial markets picking up around world...
Scoop.it

Will everyone in the world have access to a Covid vaccine? – video explainer | Society | The Guardian

Rob LW - 0
The Guardian's international correspondent, Michael Safi, explains why 'vaccine nationalisation' could scupper global efforts to kill the virus and examines what is being done to...
Scoop.it

How Iceland hammered COVID with science

Rob LW - 0
The tiny island nation brought huge scientific heft to its attempts to contain and study the coronavirus. Here’s what it learnt.
Read more
Scoop.it

3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca | The Motley Fool

Rob LW - 0
They could add up to make Moderna a much bigger winner for investors than either of the two big pharma stocks.
View Post
Scoop.it

3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca | The Motley Fool

Rob LW - 0
They could add up to make Moderna a much bigger winner for investors than either of the two big pharma stocks.
View Post
Scoop.it

Coronavirus vaccine results drive hope for economic recovery | Business | The Guardian

Rob LW - 0
Guardian analysis shows retail sales booming and financial markets picking up around world...
View Post
Scoop.it

Will everyone in the world have access to a Covid vaccine? – video explainer | Society | The Guardian

Rob LW - 0
The Guardian's international correspondent, Michael Safi, explains why 'vaccine nationalisation' could scupper global efforts to kill the virus and examines what is being done to...
View Post
Scoop.it

COVID-19: Two million more Moderna jabs secured as PM appoints new vaccine minister | UK News

Rob LW - 0
Doses of the jab 95%-effective jab could begin in the Spring, but it has yet to be approved by the UK regulator.
View Post
Scoop.it

How Iceland hammered COVID with science

Rob LW - 0
The tiny island nation brought huge scientific heft to its attempts to contain and study the coronavirus. Here’s what it learnt.
View Post

Video News

Latest Articles

Scoop.it

3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca | The Motley Fool

Rob LW - 0
They could add up to make Moderna a much bigger winner for investors than either of the two big pharma stocks.
Read more
Scoop.it

3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca | The Motley Fool

Rob LW - 0
They could add up to make Moderna a much bigger winner for investors than either of the two big pharma stocks.
Read more
Scoop.it

Coronavirus vaccine results drive hope for economic recovery | Business | The Guardian

Rob LW - 0
Guardian analysis shows retail sales booming and financial markets picking up around world...
Read more
Scoop.it

Will everyone in the world have access to a Covid vaccine? – video explainer | Society | The Guardian

Rob LW - 0
The Guardian's international correspondent, Michael Safi, explains why 'vaccine nationalisation' could scupper global efforts to kill the virus and examines what is being done to...
Read more
Scoop.it

COVID-19: Two million more Moderna jabs secured as PM appoints new vaccine minister | UK News

Rob LW - 0
Doses of the jab 95%-effective jab could begin in the Spring, but it has yet to be approved by the UK regulator.
Read more
Scoop.it

How Iceland hammered COVID with science

Rob LW - 0
The tiny island nation brought huge scientific heft to its attempts to contain and study the coronavirus. Here’s what it learnt.
Read more
Load more
Scoop.it

3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca | The Motley Fool

Rob LW - 0
They could add up to make Moderna a much bigger winner for investors than either of the two big pharma stocks.
View Post
Scoop.it

3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca | The Motley Fool

Rob LW - 0
They could add up to make Moderna a much bigger winner for investors than either of the two big pharma stocks.
View Post
Scoop.it

Coronavirus vaccine results drive hope for economic recovery | Business | The Guardian

Rob LW - 0
Guardian analysis shows retail sales booming and financial markets picking up around world...
View Post
Scoop.it

Will everyone in the world have access to a Covid vaccine? – video explainer | Society | The Guardian

Rob LW - 0
The Guardian's international correspondent, Michael Safi, explains why 'vaccine nationalisation' could scupper global efforts to kill the virus and examines what is being done to...
View Post
Scoop.it

COVID-19: Two million more Moderna jabs secured as PM appoints new vaccine minister | UK News

Rob LW - 0
Doses of the jab 95%-effective jab could begin in the Spring, but it has yet to be approved by the UK regulator.
View Post

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

We have daily and weekly curated newsletters.

Just click above to choose your options.